menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Established proof of concept for the Company’s modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humans Interim Phase 1 data from first two cohorts show NTLA-2001 was well-tolerated and achieved deep TTR reduction, with
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass. , July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its second quarter 2021 financial results
Read More

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

CAMBRIDGE, Mass. , July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the closing of an underwritten
Read More

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the pricing of an underwritten
Read More

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , June 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that it has commenced an underwritten
Read More

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response
Read More

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

CAMBRIDGE, Mass. , June 24, 2021 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta , J.D., as Executive
Read More

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

Focus will be on Development of Allogeneic Universal CAR T-Cell Therapies for Immuno -oncology and Autoimmune Diseases - Blackstone Life Sciences Commits to an Active Role and a $250 Million Financing as Sole Founding Investor - Cellex to Contribute Switchable Universal CAR-T Technology Developed
Read More

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June 26 CAMBRIDGE, Mass. , June 04, 2021 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces First Quarter 2021 Financial Results

Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND or IND-equivalent in mid-2021 to advance NTLA-5001   for acute myeloid leukemia (AML) Expect to
Read More
RSS FEEDS
PRINT PAGE